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Abstract
Summary: In this paper we build on work investigating the feasibility of human immunodefi-
ciency virus (HIV) testing in emergency departments (EDs), estimating the prevalence of
hepatitis B, C and HIV infections among persons attending two inner-London EDs, identify-
ing factors associated with testing positive in an ED. We also undertook molecular character-
isation to look at the diversity of the viruses circulating in these individuals, and the presence
of clinically significant mutations which impact on treatment and control.
Blood-borne virus (BBV) testing in non-traditional settings is feasible, with emergency
departments (ED) potentially effective at reaching vulnerable and underserved populations.
We investigated the feasibility of BBV testing within two inner-London EDs. Residual samples
from biochemistry for adults (⩾18 years) attending The Royal Free London Hospital (RFLH)
or the University College London Hospital (UCLH) ED between January and June 2015 were
tested for human immunodeficiency virus (HIV)Ag/Ab, anti-hepatitis C (HCV) and HBsAg.
PCR and sequence analysis were conducted on reactive samples. Sero-prevalence among per-
sons attending RFH and UCLH with residual samples (1287 and 1546), respectively, were
1.1% and 1.0% for HBsAg, 1.6% and 2.3% for anti-HCV, 0.9% and 1.6% for HCV RNA,
and 1.3% and 2.2% for HIV. For RFH, HBsAg positivity was more likely among persons of
black vs. white ethnicity (odds ratio 9.08; 95% confidence interval 2.72–30), with anti-HCV
positivity less likely among females (0.15, 95% CI 0.04–0.50). For UCLH, HBsAg positivity
was more likely among non-white ethnicity (13.34, 95% CI 2.20–80.86 (Asian); 8.03, 95%
CI 1.12–57.61 (black); and 8.11, 95% CI 1.13–58.18 (other/mixed)). Anti-HCV positivity
was more likely among 36–55 year olds vs. ⩾56 years (7.69, 95% CI 2.24–26.41), and less likely
among females (0.24, 95% CI 0.09–0.65). Persons positive for HIV-markers were more likely
to be of black vs. white ethnicity (4.51, 95% CI 1.63–12.45), and less likely to have one ED
attendance (0.39, 95% CI 0.17–0.88), or female (0.12, 95% CI 0.04–0.42). These results indi-
cate that BBV-testing in EDs is feasible, providing a basis for further studies to explore pro-
vider and patient acceptability, referral into care and cost-effectiveness.
Introduction
There are an estimated 180 000 persons with chronic hepatitis B (HBV) and 210 000 with
chronic hepatitis C (HCV) in the UK, roughly equating to a prevalence of 0.4% for HBV
and for HCV in 2018 [1, 2]. Similarly an estimated 101 600 persons were living with
human immunodeficiency virus (HIV) in the UK in 2017, equivalent to an estimated preva-
lence of 0.2% [3]. The undiagnosed fraction for HIV for 2017 was estimated at 8%, however
while unknown for HCV and HBV it is likely substantial. The annual unlinked anonymous
survey in people who inject drugs (PWID) estimates that half of those injecting psychoactive
drugs are unaware of their HCV-positive status (HCV report). The low diagnosed fraction for
hepatitis is likely related to the fact that many of those at risk (e.g. PWID, recent migrants,
prisoners, men who have sex with men) are socially marginalised and underserved and so
less likely to engage with traditional primary care settings. Many barriers exist that contribute
to underdiagnosis including social and individual barriers, such as lack of understanding of
their risk, fear of the diagnosis and implications, concerns about social stigma attached to
the infection and lack of knowledge about local healthcare [4, 5]; structural barriers such as
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lack of easily accessible and convenient community services and
long waiting times for appointments; and system barriers created
by complex commissioning and referral pathways as well as lack
of health professional awareness [6–8].
Testing for HIV has traditionally been targeted in risk groups
such as persons attending genitourinary medicine (GUM) ser-
vices or as part of universal antenatal screening programme
because of the risk of mother to child transmission. In the last
decade, there has been a drive to reduce barriers to HIV testing
in the UK through national recommendations to expand offer
of HIV test to non-traditional settings, such as new registrations
in general practice, all medical admissions and accident and emer-
gency in areas where HIV diagnosed prevalence was estimated at
>2 per 1000, encouraging potentially high-risk individuals to take
up testing who would not otherwise have been reached [1, 9, 10],
and aligning with NICE recommendations for universal testing
where HIV prevalence is ⩾0.2% [11].
NICE guidance in 2012 on improving offer and uptake of test-
ing for HBV and HCV includes recommended testing in primary
care, prisons and immigration removal centres, drug services and
sexual health and GUM clinics [12], with WHO recommending
universal testing where HCV prevalence is ⩾5.0% for HCV and
⩾2.0% for HBV [13]. While the offer of a HBV and HCV test
in primary care is recommended for migrants from medium or
high prevalence countries (i.e. prevalence above 2%) [14], these
recommendations are not being consistently implemented in
GP practices due to lack of awareness, workload and resource
issues [15]. Although EDs have not been explicitly mentioned
in the NICE guidance for HBV and HCV, it is a setting which
has been explored for HIV and TB testing, and so could be con-
sidered for HBV and HCV. The ED setting is universally access-
ible to all people [16–18], and therefore could be potentially
effective at reaching more vulnerable and underserved popula-
tions [4].
A number of studies investigating blood-borne virus (BBV)
testing in EDs have been carried out to look at testing implemen-
tation and uptake and prevalence of BBV in those tested. Many
studies focused on HIV testing uptake ranged from 30% to
65%, with the proportion newly diagnosed ranging from 0.06%
to 0.3% [19–22]. In 2014, nine UK EDs took part in a week
long campaign entitled ‘Going Viral’, in which combined BBV
tests were offered to patients attending the ED. During that
week, 27% of eligible patients accepted testing, with 0.8%, 0.7%
and 1.8% diagnosed HIV, HBV and HCV, respectively, with the
corresponding proportion newly diagnosed 0.3%, 0.5% and
0.7%, respectively [23]. Finally, among attendees at St Thomas’
ED, London 2016, half of persons accepted a test for either
HBV or HCV, with a positivity of 1.1% and 2.2%, respectively
[24].
While the test yields in most studies are reasonably high –
above background population rates, the variable offer and uptake
of testing renders it difficult to make any direct inferences about
prevalence of BBV in patients attending ED but does hint at
implementation challenges such as patient and provider attitudes,
entrenched practices – all of which need to be considered in an
assessment of feasibility. Equally important as expanding testing
to identify the undiagnosed population is linkage to care and
treatment; this being the ultimate goal of BBV testing strategies
to improve outcomes in the individual but also to realise public
health impact of treatment as prevention. This is particularly rele-
vant for HCV infection with the availability of direct acting anti-
viral (DAA) which can cure infection in most people [25].
Our study aims to estimate the prevalence of HBV, HCV and
HIV infections among those persons attending two inner-city
London EDs, identifying factors associated with testing positive
in an ED and describing the molecular characteristics of those
BBV-infected ED attendees. The Royal Free London NHS
Foundation Trust and University College Hospital Foundation
Trust serve very diverse populations, with a high number of atten-
dances. Local populations served by these hospitals include
Camden, Islington, Barnet, Enfield, Haringey and Westminster,
of which three out of six have high prevalence estimates for
HIV and HCV [26, 27], high rates of HCV infections among per-
sons injecting drugs [27] and diverse deprivation scores [28, 29].
Undertaking molecular characterisation provides an opportunity
to look at the diversity of the viruses circulating in these indivi-
duals and will allow for some comment to be made on the pres-
ence of clinically significant mutations which may impact on
treatment and control.
Methods
Samples
Between January and June 2015, adults (⩾18 years) attending the
ED at either The Royal Free London NHS Foundation Trust or
the University College London NHS Foundation Trust, on
whom blood samples were taken for biochemistry as part of
their routine care, were included in the study. Residual sera/
plasma of sufficient quantities were sent to the Blood-borne
Virus Unit (BBVU) at Public Health England, Colindale for
testing.
The study was undertaken as part of the National Institute for
Health Research (NIHR) Health Protection Research Unit
(HPRU) in Blood Borne and Sexually Transmitted Infections at
University College London.
Virological testing
Serological testing was undertaken on the Architect platform
(Abbott, Maidenhead, UK) for the following markers: HIV 1
and 2 Ag/Ab, anti-HCV and HBsAg. The tests were performed
in accordance to the manufacturers’ instructions. However, as
the samples originated from biochemistry laboratories using auto-
mated liquid handlers, a decision was made to consider only sam-
ples yielding signals five times above the cut-off as being reactive
to minimise any risks from cross-contamination.
Nucleic acid was extracted using QIAsymphony virus/patho-
gen DSP mini kit (Qiagen) for those samples with serological evi-
dence of HIV and/or HCV infections and using MagNApure 96
DNA Viral Nucleic Acid Small Volume kit (Roche Diagnostics,
Mannheim, Germany) for the samples with HBV markers. The
viral load was quantified by real-time PCR as previously reported
[30–32] and the extracts were analysed by PCRs for HIV [33],
HBV and HCV genotyping [34]. Next-generation sequencing
and a bioinformatic analysis were performed on the positive sam-
ples as described [35]. Consensus sequences were aligned with ref-
erence sequences for HIV, HCV and HBV using MEGA6 [36]
and a phylogenetic analysis were done using the neighbour-
joining distance matrix algorithm and the Kimura-2 parameters
model. The drug susceptibility of HCV and HIV samples was
determined using Geno2pheno[HCV] [37] and the Stanford
HIV drug resistance database genotypic interpretation algorithm
[38], respectively.
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Demographics
A minimum dataset of demographic data (age; sex; ethnicity;
time, day and month of attendance; reason for attendance; and
GP registration) was extracted from the trusts’ Patient
Administrative Systems (PAS) and linked to the subsequent test
results. Data on all ED attendees were collected to determine
how representative the tested population was. Patient’s demo-
graphics (age, sex and ethnicity) as well as time and reason for
attendance were compared. Reason for attendance was reported
using Systematized Nomenclature of Medicine-Clinical Terms
(SNOMED) and was grouped into 14 reasons to mirror those
used in a week long campaign entitled ‘Going Viral’, (in which
combined BBV tests were offered to patients attending nine UK
EDs) to allow for comparison [23]; trauma and orthopaedics,
infections, cardiac conditions, haematology, central nervous sys-
tem (CNS) conditions, respiratory conditions, gastrointestinal
conditions, urological conditions, obstetrics and gynaecological
conditions, diabetes, dermatology conditions and allergy, maxillo-
facial, ENT conditions and ophthalmology, psychological and
social, and not reported. Persons were classified as re-attending
if there was more than one attendance recorded during the
study period.
Pseudo-anonymisation and unlinking
Samples were pseudonymised and assigned a unique study ID.
After linking with the PAS extract and prior to testing samples,
all individual hospital and laboratory numbers were irreversibly
removed so that the final dataset did not contain sufficient infor-
mation to identify individuals. Only one sample per individual
was included in the analysis.
Statistical analysis
Descriptive statistics were given for all persons presenting at an
ED, and for persons testing positive for a BBV. Data were dedu-
plicated prior to anonymisation and through sequencing if posi-
tive to ensure that only one result per individual was included
within the analysis, as re-attenders testing positive would lead
to an overestimate of seroprevalence, or an underestimate
among re-attenders testing negative. The χ2 or the Fisher’s exact
test was used to compare categorical data. Ninety-five per cent
confidence intervals (CI) were estimated. Factors associated with
testing positive for a BBV were assessed through univariate logis-
tic regression analysis of the following variables: gender, age, eth-
nicity, re-attendance, time, day and reason of attendance.
Statistical analyses were performed using STATA version 13.
Ethics
Ethical approval was obtained for the Unlinked Anonymous
Testing (UAT) approach via the Integrated Research Approval
System (IRAS) proportionate review service. Specific consent
was not sought as individual patients could not be linked to
their test results and were not contacted and informed of their
serological status.
Results
During the 6-month period January–June 2015, 75 910 persons
attended two emergency departments (ED) within London, 30
052 persons attended The Royal Free Hospital (RFH), and 45
858 attended the University College London Hospital (UCLH).
Residual blood samples referred for BBV testing at PHE were
available on 2833 persons overall: 1287 and 1546 persons from
RFH and UCLH, respectively.
Table 1 presents the distribution of the 75 910 persons attend-
ing the two ED within the 6-month period, for both hospitals the
majority of persons reported being registered with a GP, and of
white ethnicity. The median age of persons attending RFH was
42 years (IQR: 29–61) and for the UCLH 35 years (IQR: 26–
52). The commonest reason (over a third) for attendance at
both EDs was trauma and orthopaedics, followed by gastrointes-
tinal complaints.
Although a low proportion of persons attending the EDs dur-
ing the study time period had biochemistry residual samples
available for BBV testing (3.4% at UCL and 4.3% RFH; 3.7% over-
all), the distribution of persons by sex and ethnicity for whom a
blood sample was taken was similar to that for all persons attend-
ing the EDs, with just over 50% being female and over 65% being
white (Table 1). The majority of ED attendees reported being
registered with a GP regardless of whether a residual sample
was available, although a higher proportion were GP-registered
among RFH compared with UCLH ED attendees. Compared
with all ED attendees, persons for whom a blood sample was
taken at both EDs were older, and more likely to re-attend.
While all patients were more likely to attend on a weekday and
between the hours 00:00–07:59 am at both EDs, these proportions
were higher among those for whom a residual blood sample was
available at UCLH. After trauma and orthopaedics, the most com-
mon reason for attendance among those with a residual sample
was cardiac and urological at RFH, and CNS and infections at
UCLH (Table 1).
The sero-prevalence rates for samples from RFH and UCLH,
respectively, were 1.1% (n = 14) and 1.0% (n = 15) for HBsAg;
1.6% (n = 21) and 2.3% (n = 35) for anti-HCV; 0.9% (n = 12)
and 1.6% (n = 25) for HCV RNA; and 1.3% (n = 17) and 2.2%
(n = 34) for anti-HIV and p24Ag (Table 2). The median age for
those testing positive was 55 years (IQR: 35–62), 57 years (IQR:
49–70), 60 years (IQR: 51–72) and 55 years (IQR: 48–63) for
HBsAg, anti-HCV, HCV RNA, and anti-HIV and p24Ag, respect-
ively, for persons attending RFH and 52 years (IQR: 30–63), 45
years (IQR: 38.5–54), 43 years (IQR: 38–52) and 43 years (IQR:
32–55) for HBsAg, anti-HCV, HCV RNA, and anti-HIV and
p24Ag, respectively, for those attending UCLH. Four persons
attending UCLH were HIV/HCV coinfected, with no coinfections
identified among those attending RFH. Persons tested whilst
attending RFH and UCLH ED are characterised in Tables 3 and 4,
respectively.
Nine (64%) and 10 (67%) of the HBsAg-reactive samples from
RFH and UCLH, respectively, were HBV DNA-positive.
Collective sequence and phylogenetic analysis showed the pres-
ence of all the five major HBV genotypes reflecting the diversity
of the HBV-infected population in the UK (genotype A: n = 8, B:
n = 1, C: n = 3, D: n = 2, E: n = 5). Where the information was
available, the HBV genotype was consistent with the ethnicity
of the individual. Similar analysis undertaken on the 12 and 25
HCV PCR-positive samples from RFH and UCLH, respectively,
indicated the 1a (n = 14) and 3a (n = 11) viruses to be the most
common with a range of other genotypes also noted (genotype
1b: n = 1, 2a: n = 1, 2b: n = 4, 3b: n = 1, 3 h: n = 1, 4a: n = 3, 4v:
n = 1). The majority of HIV-reactive samples, 86% for RFH and
74% for UCLH, were RNA-negative with genotype determination
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Table 1. Demographics of persons attending two emergency departments in London, Royal Free Hospital and University College London Hospital, between January
and June 2015
Royal Free Hospital University College London Hospital
ED attendees
Residual blood
sample taken for
biochemistry ED attendees
Residual blood
sample taken for
biochemistry
n = 30 052 % n = 1287 % n = 45 858 % n = 1546 %
Sex
Male 14 170 47.2 608 47.2 22 515 49.1 749 48.4
Female 15 881 52.8 679 52.8 23 341 50.9 797 51.6
Not reported 1 2
Age group
18–35 11 758 39.1 284 22.1 23 694 51.7 503 32.5
36–55 8916 29.7 353 27.4 12 776 27.9 451 29.2
⩾56 9378 31.2 650 50.5 9388 20.5 592 38.3
Ethnicity
White 17 912 64.8 784 65.0 20 829 70.3 829 73.1
Asian 3820 13.8 180 14.9 2885 9.7 96 8.5
Black 2561 9.3 109 9.0 2868 9.7 105 9.3
Other/mixed 3370 12.2 134 11.1 3053 10.3 104 9.2
Not reported 2389 80 16 223 412
Re-attendance
Yes 5652 18.8 552 42.9 6866 15.0 577 37.3
No 24 400 81.2 735 57.1 38 992 85.0 969 62.7
Registered with a GP
Yes 28 058 93.4 1244 96.7 35 720 77.9 1319 85.3
No 1994 6.6 43 3.3 10 138 22.1 227 14.7
Time of attendance
00:00–07:59 3512 11.7 247 19.2 6026 13.1 120 7.8
08:00–15:59 14 249 47.4 526 40.9 21 732 47.4 978 63.3
16:00–23:59 12 291 40.9 514 39.9 18 100 39.5 448 29.0
Day
Weekday 21 800 72.5 800 62.2 34 308 74.8 1250 80.9
Weekend 8252 27.5 487 37.8 11 550 25.2 296 19.1
Reason for attendance
Trauma and orthopaedics 9512 36.4 210 19.4 16 256 43.6 238 21.0
Infections 2640 10.1 112 10.4 2639 7.1 113 10.0
Cardiac conditions 1850 7.1 141 13.0 1119 3.0 56 4.9
Haematology 102 0.4 10 0.9 78 0.2 7 0.6
Central nervous system conditions 1286 4.9 72 6.7 3141 8.4 178 15.7
Respiratory conditions 1340 5.1 79 7.3 2122 5.7 100 8.8
Gastrointestinal conditions 3348 12.8 202 18.7 3996 10.7 234 20.6
Urological conditions 1556 5.9 103 9.5 1570 4.2 67 5.9
Obstetrics and gynaecological conditions 849 3.2 39 3.6 1637 4.4 44 3.9
Diabetes 115 0.4 10 0.9 129 0.3 5 0.4
(Continued )
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possible in three samples, two of which were HIV-1 subtype B
and one CRF02_AG. Additional analysis showed the presence
of motifs linked to antiviral resistance in one sample.
We identified factors associated with a positive result using a
univariable model; numbers were too small to use a multivariate
model. Among persons attending the RFH ED, attendance infor-
mation was available for 12/14 persons diagnosed as HBsAg-
positive, all those diagnosed with HCV [20], and 15/17 persons
diagnosed positive for anti-HIV and p24Ag. Persons testing posi-
tive for HBsAg were more likely to be of black ethnicity when
compared with persons of white ethnicity (odds ratio (OR)
9.08; 95% CI 2.72–30). Persons testing anti-HCV-positive were
less likely to be female when compared with men (OR 0.15,
95% CI 0.04–0.50 and OR 0.18, 95% CI 0.04–0.81 for
anti-HCV and HCV PCR, respectively). There were no factors
associated with testing anti-HIV- and p24Ag-positive (Table 5).
Among persons attending UCLH, attendance information was
available for 12/15 persons diagnosed as HBsAg-positive, 24/35
persons diagnosed anti-HCV-positive, 15/25 of those diagnosed
positive for HCV PCR and 25/34 persons diagnosed positive for
anti-HIV and p24Ag. Persons testing positive for HBsAg were
more likely to be of non-white ethnicity when compared with
white ethnicity (OR 13.34, 95% CI 2.20–80.86; OR 8.03, 95% CI
1.12–57.61 and OR 8.11, 95% CI 1.13–58.18, respectively, for
Asian, black and other/mixed ethnicity), persons testing positive
for anti-HCV were less likely to be female when compared with
males (OR 0.24, 95% CI 0.09–0.65), but more likely to be aged
between 36 and 55 years for both persons anti-HCV-positive
and PCR-positive when compared with 56 years and over (OR
7.69, 95% CI 2.24–26.41 and OR 6.69, 95% CI 1.46–30.68,
respectively). Persons anti-HIV- and p24Ag-positive were also
less likely to be female when compared with males (OR 0.12,
95% CI 0.04–0.42), were more likely to be of black ethnicity
when compared with white ethnicity (OR 4.51, 95% CI 1.63–
12.45) and less likely to have attended the ED only once during
the 6-month period compared with multiple attendances (OR
0.39, 95% CI 0.17–0.88) (Table 6).
Discussion
To our knowledge, this is the first study to estimate seroprevalence as
well as describe the viral diversity of all three BBVs ED attendees
through untargeted residual blood sample testing in two central
London EDs. While not an assessment of feasibility of BBV testing
in itself, our findings contribute to the growing body of evidence
assessing how feasible, acceptable and economically viable BBV test-
ing is within the ED setting. During the 6-month study period, the
seroprevalence rates of BBVs among persons attending two EDs in
London, who had blood taken as part of routine care and a residual
sample available for testing, were 1.1% and 1.0% for HBsAg, 1.6%
and 2.3% for anti-HCV, 0.9% and 1.6% for HCV RNA and 1.3%
and 2.2% for anti-HIV and p24Ag, within the RFH and UCLH
EDs, respectively. These proportions are higher than general popu-
lation prevalence estimates and so provide some support of the
assumption that higher risk groups for BBV may attend urban
EDs. Seroprevalences in our study are not necessarily directly com-
parable with other studies estimating seropositivity in EDs as many
of these studies actually measure positivity rates through targeted or
risk-based testing and so do not actually estimate seroprevalence
among all ED attendees. Additionally, the impact of new curative
treatments, e.g. DAAs for HCV and ramp up of case finding may
result in lower seroprevalences in the ED-attending population.
Table 1. (Continued.)
Royal Free Hospital University College London Hospital
ED attendees
Residual blood
sample taken for
biochemistry ED attendees
Residual blood
sample taken for
biochemistry
n = 30 052 % n = 1287 % n = 45 858 % n = 1546 %
Dermatology conditions and Allergy 892 3.4 31 2.9 1039 2.8 19 1.7
Maxillofacial, ENT conditions and ophthalmology 1831 7.0 43 4.0 2574 6.9 47 4.1
Psychological and social 842 3.2 29 2.7 978 2.6 26 2.3
Not reported 3889 206 8580 412
Proportions are calculated where information has been reported.
Table 2. Sero-prevalence of BBV in persons attending two emergency departments in London, Royal Free Hospital and University College London Hospital, between
January and June 2015, for whom residual blood samples were available
ED attendees
Blood sample taken
for biochemistry HBsAg-positive Anti-HCV-positive HCV PCR-positive
Anti-HIV- and
p24Ag-positive
n % n % n % n % n %
Royal Free Hospital 30 052 1287 4.3 14 1.1 21 1.6 12 0.9 17 1.3
University College
London Hospital
45 858 1546 3.4 15 1.0 35 2.3 25 1.6 34 2.2
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Table 3. Demographics and positivity rate of persons attending The Royal Free Hospital emergency department between January and June 2015 for whom a
residual sample was available and tested for BBV
Persons tested
HBsAg-positive
Anti-HCV-
positive
HCV PCR-
positive
Anti-HIV- and
p24Ag-positive
n = 1287 n = 12 % n = 21 % n = 12 % n = 15 %
Sex
Male 608 6 1.0 18 3.0 10 1.6 9 1.5
Female 679 6 0.9 3 0.4 2 0.3 6 0.9
Age group
18–35 284 4 1.4 0 0.0 0 0.0 4 1.4
36–55 353 4 1.1 9 2.5 5 1.4 4 1.1
⩾56 650 4 0.6 12 1.8 7 1.1 7 1.1
Ethnicity
White 784 5 0.6 10 1.3 4 0.5 10 1.3
Asian 180 1 0.6 4 2.2 2 1.1 3 1.7
Black 109 6 5.5 3 2.8 3 2.8 1 0.9
Other/mixed 134 0 0.0 2 1.5 1 0.7 1 0.7
Not reported 80 0 0.0 2 2.5 2 2.5 0 0.0
Re-attendance
Yes 552 6 1.1 13 2.4 7 1.3 3 0.5
No 735 6 0.8 8 1.1 5 0.7 12 1.6
Registered with a GP
Yes 1244 12 1.0 20 1.6 12 1.0 14 1.1
No 43 0 0.0 1 2.3 0 0.0 1 2.3
Time of attendance
00:00–07:59 247 5 2.0 3 1.2 1 0.4 1 0.4
08:00–15:59 526 2 0.4 11 2.1 6 1.1 7 1.3
16:00–23:59 514 5 1.0 7 1.4 5 1.0 7 1.4
Day of attendance
Weekday 800 7 0.9 14 1.8 7 0.9 10 1.3
Weekend 487 5 1.0 7 1.4 5 1.0 5 1.0
Reason for attendance
Trauma and orthopaedics 210 1 0.5 3 1.4 1 0.5 2 1.0
Infections 112 1 0.9 2 1.8 0 0.0 1 0.9
Cardiac conditions 141 1 0.7 6 4.3 6 4.3 0 0.0
Haematology 10 0 0.0 0 0.0 0 0.0 0 0.0
Central nervous system conditions 72 0 0.0 0 0.0 0 0.0 1 1.4
Respiratory conditions 79 0 0.0 2 2.5 1 1.3 4 5.1
Gastrointestinal conditions 202 5 2.5 1 0.5 0 0.0 0 0.0
Urological conditions 103 0 0.0 3 2.9 1 1.0 1 1.0
Obstetrics and gynaecological conditions 39 0 0.0 0 0.0 0 0.0 0 0.0
Diabetes 10 0 0.0 0 0.0 0 0.0 0 0.0
Dermatology conditions and allergy 31 1 3.2 0 0.0 0 0.0 0 0.0
Maxillofacial, ENT conditions and ophthalmology 43 2 4.7 0 0.0 0 0.0 0 0.0
Psychological and social 29 0 0.0 0 0.0 0 0.0 0 0.0
Not reported 206 1 0.5 4 1.9 3 1.5 6 2.9
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Table 4. Demographics and positivity rate of persons attending the University College Hospital London emergency department between January and June 2015 for
whom a residual sample was available and tested for BBV
Persons tested
HBsAg-
positive
Anti-HCV-
positive
HCV PCR-
positive
Anti-HIV- and
p24Ag-positive
n = 1546 n = 12 % n = 24 % n = 15 % n = 25 %
Sex
Male 749 6 0.8 19 2.5 10 1.3 22 2.9
Female 797 6 0.8 5 0.6 5 0.6 3 0.4
Age group
18–35 503 5 1.0 4 0.8 3 0.6 8 1.6
36–55 451 3 0.7 17 3.8 10 2.2 11 2.4
⩾56 592 5 0.8 3 0.5 2 0.3 6 1.0
Ethnicity
White 829 2 0.2 18 2.2 11 1.3 11 1.3
Asian 96 3 3.1 0 0.0 0 0.0 1 1.0
Black 105 2 1.9 1 1.0 1 1.0 6 5.7
Other/mixed 104 2 1.9 1 1.0 1 1.0 4 3.8
Not reported 412 3 0.7 4 1.0 2 0.5 3 0.7
Re-attendance
Yes 577 6 1.0 14 2.4 9 1.6 15 2.6
No 969 6 0.6 10 1.0 6 0.6 10 1.0
Registered with a GP
Yes 1319 8 0.6 18 1.4 10 0.8 22 1.7
No 227 4 1.8 6 2.6 5 2.2 3 1.3
Time of attendance
00:00–07:59 120 2 1.7 3 2.5 2 1.7 2 1.7
08:00–15:59 978 6 0.6 14 1.4 9 0.9 16 1.6
16:00–23:59 448 4 0.9 7 1.6 4 0.9 7 1.6
Day of attendance
Weekday 1250 10 0.8 20 1.6 12 1.0 20 1.6
Weekend 296 2 0.7 4 1.4 3 1.0 5 1.7
Reason for attendance
Trauma and orthopaedics 238 2 0.8 7 2.9 6 2.5 6 2.5
Infections 113 0 0.0 2 1.8 1 0.9 2 1.8
Cardiac conditions 56 1 1.8 0 0.0 0 0.0 0 0.0
Haematology 7 0 0.0 0 0.0 0 0.0 0 0.0
Central nervous system conditions 178 1 0.6 2 1.1 2 1.1 3 1.7
Respiratory conditions 100 1 1.0 4 4.0 3 3.0 1 1.0
Gastrointestinal conditions 234 2 0.9 3 1.3 1 0.4 1 0.4
Urological conditions 67 1 1.5 0 0.0 0 0.0 0 0.0
Obstetrics and gynaecological conditions 44 2 4.5 0 0.0 0 0.0 0 0.0
Diabetes 5 0 0.0 0 0.0 0 0.0 0 0.0
Dermatology conditions and allergy 19 0 0.0 0 0.0 0 0.0 2 10.5
Maxillofacial, ENT conditions and ophthalmology 47 0 0.0 1 2.1 0 0.0 2 4.3
Psychological and social 26 0 0.0 1 3.8 0 0.0 2 7.7
Not reported 412 2 0.5 4 1.0 2 0.5 6 1.5
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Table 5. Factors associated with testing positive for a BBV among persons attending The Royal Free Hospital emergency department between January and June 2015
HBsAg-positive Anti-HCV-positive HCV PCR-positive Anti-HIV- and p24Ag-positive
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Sex
Male 1 0.848 1 1 0.009 1 0.319
Female 0.89 0.29–2.79 0.15 0.04–0.50 <0.001 0.18 0.04–0.81 0.59 0.21–1.68
Age group
18–35 2.31 0.57–9.29 * 1.31 0.38–4.52
36–55 1.85 0.46–7.45 1.39 0.58–3.33 1.32 0.42–4.19 1.05 0.31–3.62 0.912
⩾56 1 0.461 1 0.464 1 0.641 1
Ethnicity
White 1 0.002 1 0.632 1 0.227 1 0.227
Asian 0.87 0.10–7.50 1.76 0.55–5.67 2.19 0.40–12.06 1.31 0.36–4.82
Black 9.08 2.72–30.27 2.19 0.59–8.09 5.52 1.22–25.00 0.72 0.09–5.65
Other/mixed * 1.17 0.25–5.41 1.47 0.16–13.22 0.58 0.07–4.58
Re-attendance
Yes 1 0.619 1 0.078 1 0.281 1 0.06
No 0.75 0.24–2.33 0.46 0.19–1.11 0.53 0.17–1.69 3.04 0.85–10.82
Registered with a GP
Yes * 1 0.731 * 1 0.523
No * 1.46 0.19–11.11 * 2.09 0.27–16.28
Time of attendance
00:00–07:59 5.41 1.04–28.10 0.38 0.08–1.74 0.35 0.04–2.94 0.3 0.04–2.46
08:00–15:59 1 0.099 1 0.349 1 0.553 1 0.379
16:00–23:59 2.57 0.50–13.33 0.65 0.25–1.68 0.85 0.26–2.81 1.02 0.36–2.94
Day of attendance
Weekday 1 0.785 1 0.665 1 0.785 1 0.715
Weekend 1.18 0.37–3.72 0.82 0.33–2.04 1.18 0.37–3.72 0.82 0.28–2.41
Reason for attendance
Trauma and orthopaedics 1 0.26 1 0.22 1 0.072 1 0.264
Infections 1.88 0.12–30.39 1.25 0.21–7.62 * 0.94 0.08–10.45
Cardiac conditions 1.49 0.09–24.06 3.07 0.75–12.47 9.29 0.75–12.47 *
Haematology * * * *
Central nervous system conditions * * * 1.46 0.13–16.40
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Albeit undertaken on limited numbers, molecular character-
isation demonstrated the diversity of viruses circulating in
BBV-infected populations, noting that genotypic information is
relevant for the choice of antiviral treatment in many of these
patients. The expected availability of HCV pan-genotypic therap-
ies will remove this limitation to treatment, but there is a need for
vigilance for anti-viral resistance motifs in circulating strains.
Due to patients attending ED not all requiring biochemistry
tests done, compounded by laboratory work load and changes
in staff which impacted on implementation of the study protocol
in the laboratories, the proportion of biochemistry residual sam-
ples available for BBV testing among ED attendees was low.
However, we actually were able to test almost 3000 samples,
which is not an insignificant sample size. Reassuringly, the ED
attendees from whom residual blood samples were obtained had
overall similar characteristics (age, ethnicity and registration
with GP, predominant reason for attendance) to the total
ED-attending population in those hospitals indicating that they
were generally representative of the ED population. A notable
exception was that the attendees with blood samples were older
and were more likely to re-attend. This likely corresponds to
the fact that older persons are more likely to have health condi-
tions that result in more acute hospital attendances and therefore
have an episode of care in which blood tests are taken. Persons
were de-duplicated to ensure only one attendance was presented
within the results and represented persons not attendances.
Both hospitals within which the EDs reside are within the bor-
ough of Camden, London, which has high estimated prevalence
for both HCV and HIV (152 and 38 per 100 000, respectively)
[26, 27], alongside high rates of hospital admissions for
HCV-related ESLD and HCC (13.3 per 100 000) [27]. The
University of College London Hospital is also the main hospital
for the borough of Islington, where prevalence for HCV is 75
per 100 000, and for HIV 32 per 100 000 [26, 27]. The borough
of Islington contains a higher proportion of disadvantaged per-
sons, with Islington ranked the 13th most deprived area in
England compared with Camden which is ranked the 69th most
deprived area [29]. Forty-four per cent of persons within the bor-
ough of Islington were living in the 20% most deprived areas,
compared with 27% of those living in borough of Camden [28].
The borough of Camden is also situated next to Westminster,
which has the highest number of rough sleepers in England
[39], in whom increased risk of some BBV has been described
[40]. The two areas of Camden have an average index of multiple
deprivation, with average or higher levels for income, employ-
ment, education and crime. However, The Royal Free resides in
an area with a health deprivation within the lowest 30% in
England, and UCLH resides within an area that is in the lowest
20% for housing, and lowest 10% for living environment [29].
Those attending the ED for The Royal Free attendees were
older than those attending UCLH, whereas UCLH attendees
had a higher proportion of persons not registered with a general
practitioner
The high proportion of persons anti-HIV-reactive, but HIV
RNA-negative is suggestive of viral suppression because of anti-
retroviral treatment and implies that many of the people testing
positive for HIV were already aware of their diagnosis and receiv-
ing treatment. However, although the UAT methodology meant it
was not possible to differentiate persons previously undiagnosed,
these findings were similar to the estimates, identified through
opt-out testing at nine UK EDs across the UK where persons pre-
viously undiagnosed could be identified [23]. Ethnicity was
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Table 6. Factors associated with testing positive for a BBV among persons attending the University College London Hospital emergency department between January and June 2015
HBsAg-positive Anti-HCV-positive HCV PCR-positive Anti-HIV- and p24Ag-positive
OR 95% CI P value OR 95% CI P value OR 95% CI P value OR 95% CI P value
Sex
Male 1 0.914 1 0.002 1 0.153 1 <0.001
Female 0.94 0.30–2.93 0.24 0.09–0.65 0.47 0.16–1.37 0.12 0.04–0.42
Age group
18–35 0.94 0.25–3.52 1.57 0.35–7.07 1.77 0.29–10.63 1.58 0.54–4.58
36–55 0.79 0.19–3.31 7.69 2.24–26.41 6.69 1.46–30.68 2.44 0.90–6.65
⩾56 1 0.945 1 <0.001 1 0.009 1 0.2
Ethnicity
White 1 0.014 1 0.466 1 0.906 1 0.028
Asian 13.34 2.20–80.86 * * 0.79 0.10–6.13
Black 8.03 1.12–57.61 0.43 0.06–3.28 0.72 0.09–5.59 4.51 1.63–12.45
Other/mixed 8.11 1.13–58.18 0.44 0.06–3.31 0.72 0.09–5.65 2.97 0.93–9.52
Re-attendance
Yes 1 0.37 1 0.036 1 0.074 1 0.021
No 0.59 0.19–1.85 0.42 0.19–0.95 0.39 0.14–1.11 0.39 0.17–0.88
Registered with a GP
Yes 1 0.104 1 0.182 1 0.069 1 0.695
No 2.94 0.88–9.84 1.96 0.77–5.00 2.95 1.00–8.71 0.79 0.23–2.66
Time of attendance
00:00–07:59 2.75 0.55–13.76 1.77 0.50–6.23 1.82 0.39–8.55 1.02 0.23–4.49
08:00–15:59 1 0.505 1 0.708 1 0.758 1 0.994
16:00–23:59 1.46 0.41–5.20 1.09 0.44–2.73 0.97 0.30–3.17 0.95 0.39–2.34
Day of attendance
Weekday 1 1 0.752 1 0.933 1 0.913
Weekend 0.84 0.18–3.87 0.84 0.29–2.48 1.06 0.30–3.77 1.06 0.39–2.84
Reason for attendance
Trauma and orthopaedics 1 0.694 1 0.628 1 0.228 1 0.089
Infections * 0.59 0.12–2.91 0.35 0.04–2.90 0.7 0.14–3.51
Cardiac conditions 2.15 0.19–24.09 * * *
Haematology * * * *
Central nervous system conditions 0.67 0.06–7.41 0.38 0.08–1.83 0.44 0.09–2.20 0.66 0.16–2.69
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identified as a factor associated with testing positive for HBsAg
and HIV, with persons of black or Asian ethnicity more likely
to test positive for HBsAg and black or other/mixed more likely
to test positive for HIV. Unfortunately, country of birth could
not be explored as it was poorly recorded on hospital systems.
Sex and age were associated with testing positive for HCV, with
males and persons aged 36–55 years being more likely to be
infected.
Overall males were more likely to test positive for HCV and
HIV which is consistent with published literature [17, 41–47]
where males are identified at greater risk of BBVs through par-
ticular adult behavioural risk factors including sex between
men, injecting drug use and homelessness (likely confounded
by substance abuse and other risk factors). A higher proportion
of HBV-infected persons were of non-white ethnicity compared
with those testing positive for HCV and HIV, which, assuming
some associations between country of birth and ethnicity in peo-
ple attending EDs, is consistent with the known burden of chronic
HBV among non-UK-born persons where acquisition was in high
endemic countries prior to migration to the UK [48].
The median age of persons testing positive for all three BBV
was older than the ED attendees, and in particular persons aged
36–55 years were disproportionally affected by HCV. This is con-
sistent with laboratory reports for England and Wales where 53%
of persons positive for anti-HCV were aged 35–54 years. Going
Viral, a campaign to offer opt-out BBV testing to all adult patients
who were already having a blood test as part of routine ED care,
also found peak prevalence of HCV among men aged 35–44 years
[23]. The authors go on to discuss targeted HCV testing for par-
ticular age groups, which has been recommended within the USA
following high prevalence of undiagnosed HCV infections among
persons born between 1945 and 1965.
Although this study suggests it is possible to identify people
with BBVs within EDs, there are several aspects of operationalis-
ing testing in EDs that should be considered, including intrinsic
(patient-specific) and extrinsic (structural, system and health
worker) enablers and barriers to testing. Among staff, ‘lack of
time’, ‘not a priority’ and ‘not medically indicated’ were reasons
for not considering a patient for a test [49], and among registrars
in a UK teaching hospital undertaking a survey for HIV testing
practices, 40% indicated that they had not performed an HIV
test on a patient they considered high risk, with the main contrib-
uting factor reported as uncertainties with regards counselling the
patient [50]. Alternatively, a patient’s perception of risk can also
be a factor, when ED patients were asked about their perceived
risk, only 37.9% of persons reporting high-risk behaviour recog-
nised the need for an HIV test [51].
Although the ED is a setting which may identify those who
would not ordinarily consider themselves at risk and therefore
seek testing, linkage to a holistic range of health and social care
services is a key component which cannot be ignored if better
health outcomes are to be realised. It is important to ensure
those diagnosed have access to BBV treatments which offer
both individual and population benefits in terms of preventing
disease progression (and for HCV cure) as well as preventing
onward transmission. Equally vital is patient access to services
supporting behavioural change and key preventative measures
such as offering hepatitis A and B vaccination, provision of needle
exchange and drug addiction treatment, and pre-exposure
prophylaxis against HIV, as appropriate to the patient’s needs.
Estimates of HCV cascade of care using surveillance data from
sentinel English laboratories in 2005–2014 showed a low uptake
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of HCV treatment overall regardless of where the patient was
tested (11.9%), with treatment uptake among those initially
diagnosed in EDs 7.9%, higher than drug services and prisons
where HCV testing is traditionally conducted (6.6% and 5.9%,
respectively) [52]. Most BBV testing studies in EDs including
an assessment of linkage to care were HIV-focused and conducted
in the USA, with the proportion of individuals linked into care
ranging from 29% to 100%, with individuals being lost before
confirmatory testing if point of care tests were used, not returning
for confirmatory results, leaving before preliminary results can be
given, being uncontactable, or refusing treatment [23, 53–63].
Where HBV and HCV testing in EDs was the focus, linkage
to care was worse for those with HCV as illustrated by the
‘VirA&Emic’ ED testing study at St Thomas’ Hospital in
London, which found contacting patients following a diagnosis
to ensure onward access to care difficult with two out of three
of those HCV-positive either homeless or not registered with
the correct address, resulting in only 33% of persons being con-
tacted, compared with 52% for persons diagnosed with HBV
[64]. Furthermore, of those who required further care, only one
person diagnosed with HBV did not attend their appointment,
compared with 11 of those diagnosed with HCV. The disparity
between infections was also found in an opt-out ED screening
programme in Dublin between 2014 and 2015, where linkage to
care for new patients was higher for those diagnosed with HIV
and HBV compared with HCV (100%, 95% and 74%, respect-
ively) [63]. Finally, Orkin et al. [23] reported linkage to care for
those newly vs. previously diagnosed, with 66% of those newly
diagnosed linked into care, and 59% retained in care, whereas
the respective figures for those previously diagnosed were 50%
and 20%.
Although the UAT approach has its strengths, as it is more
accurate and representative by eliminating selection bias by per-
ceived risk or the way the test is offered, the UAT screening
approach limits the ability to establish whether seropositive indi-
viduals had been previously diagnosed; this makes it difficult to
demonstrate the ‘added value’ of BBV testing within this setting.
However, the infection rates at these two EDs were similar to that
of other ED studies where testing was actively offered, and higher
than background population prevalence. Prevalence of BBV
may, however, be underestimated in our study as not all atten-
dances had blood taken as part of routine care. In addition,
the findings of our study may not be generalisable to all EDs,
in particular those situated outside of central London as the
London boroughs for which these EDs are situated and serve
have high HCV and HIV prevalence. Compared with other stud-
ies, a lower proportion of persons had biochemistry samples
available which was likely due to not all ED patients having
blood samples done, laboratory work load and changes in
staff, so that not all biochemistry samples were aliquoted and
sent to PHE. However, this would have occurred randomly
rather than systematically.
In summary, this study’s findings demonstrate that universal
screening of ED attendees for all BBVs will yield positive cases
in urban, diverse populations with relatively high prevalence.
However, there is the need for further evaluation of the additional
yield in terms of new diagnoses as opposed to repeat diagnoses,
whether the population profiles of those tested within the ED dif-
fer from traditional settings, and whether disease prevalence
thresholds for implementing BBV testing in an ED setting
might be considered. High positivity rates and high utilisation
of acute ED services among populations with particular
demographics may equate to identification of vulnerable groups
who do not seek healthcare in primary care and may also be at
greater risk, or who may be unaware of their infection or have
previously been diagnosed but have not re-engaged in care. Our
findings lay the foundation for further studies to explore provider
and patient acceptability, undiagnosed yield, linkage to care and
cost-benefits of BBV testing in EDs, to enable targeted public
health action to address the challenge of undiagnosed infections
in vulnerable populations.
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